Department of Cardiology, National Heart Centre Singapore, Singapore.
Ann Acad Med Singap. 2020 May;49(5):273-284.
Chronic kidney disease (CKD) is a significant comorbidity in aortic stenosis (AS) patients. We examined the impact of baseline CKD, postoperative acute kidney injury (AKI) and CKD progression on clinical outcomes in patients who underwent transcatheter aortic valve implantation (TAVI).
Consecutive patients with severe AS who underwent TAVI were classified into CKD stages 1-2 (≥60 mL/min/1.72m), 3 (30-59 mL/min/1.73m) and 4-5 (<30 mL/min/1.73m or dialysis) based on estimated glomerular filtration rate (eGFR). Primary outcome was mortality and secondary outcomes included 1-year echocardiographic data on aortic valve area (AVA), mean pressure gradient (MPG) and aortic regurgitation (AR).
A total of 216 patients were included. Higher eGFR was associated with lower overall mortality (adjusted hazards ratio [AHR] 0.981, 95% confidence interval [CI] 0.968-0.993, = 0.002). CKD 4-5 were associated with significantly higher mortality from non-cardiovascular causes ( <0.05). Patients with CKD 3-5 had higher incidence of moderate AR than those with CKD 1-2 ( = 0.010); no difference in AVA and MPG was seen. AKI patients had higher mortality ( = 0.008), but the effect was attenuated on multivariate analysis (AHR 1.823, 95% CI 0.977-3.403, = 0.059). Patients with CKD progression also had significantly higher mortality (AHR 2.969, 95% CI 1.373-6.420, = 0.006).
CKD in severe AS patients undergoing TAVI portends significantly higher mortality and morbidity. Renal disease progression impacts negatively on outcomes and identifies a challenging subgroup of patients for optimal management.
慢性肾脏病(CKD)是主动脉瓣狭窄(AS)患者的重要合并症。我们研究了基线 CKD、术后急性肾损伤(AKI)和 CKD 进展对接受经导管主动脉瓣植入术(TAVI)的患者临床结局的影响。
连续接受 TAVI 的严重 AS 患者根据估算肾小球滤过率(eGFR)分为 CKD 1-2 期(≥60mL/min/1.72m)、3 期(30-59mL/min/1.73m)和 4-5 期(<30mL/min/1.73m 或透析)。主要结局为死亡率,次要结局包括 1 年经胸超声心动图主动脉瓣面积(AVA)、平均压力梯度(MPG)和主动脉瓣反流(AR)的数据。
共纳入 216 例患者。较高的 eGFR 与较低的全因死亡率相关(调整后的风险比 [AHR] 0.981,95%置信区间 [CI] 0.968-0.993, = 0.002)。CKD 4-5 与非心血管原因死亡率显著升高相关(<0.05)。与 CKD 1-2 相比,CKD 3-5 患者中中度 AR 的发生率更高( = 0.010);AVA 和 MPG 无差异。AKI 患者死亡率更高( = 0.008),但多变量分析时作用减弱(AHR 1.823,95%CI 0.977-3.403, = 0.059)。CKD 进展患者的死亡率也显著升高(AHR 2.969,95%CI 1.373-6.420, = 0.006)。
严重 AS 患者 TAVI 术后 CKD 预示着更高的死亡率和发病率。肾脏疾病进展对结局产生负面影响,并确定了一个具有挑战性的患者亚组,需要进行最佳管理。